Fifth Street Finance Corp. (FSC) was downgraded by Barclays from an ‘Overweight’ rating to an ‘Equal Weight’ rating in a research note issued to clients and investors on Tuesday. They currently have an $8.00 from $11.00 price objective on the stock.
Barclays‘ target price suggests a potential downside of about 37% from the company’s current price of $6.97. The stock is currently trading on heavy volume with 5.2 million shares changing hands, well ahead of its three month daily average of 1.4 million shares.
In the past 52 weeks, FSC shares have traded between a low of $6.94 and a high of $10.20. Shares are down 27.58% year-over-year, and 12.93% year-to-date.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) are up 1.1% to $402.36 in mid-day trading Tuesday despite a downgraded to ‘Neutral’ from ‘Overweight’ by analysts at Piper Jaffray this morning. Analysts at the brokerage firm downgraded the name following the company’s Q4 earnings of $2.79 per share, $0.04 worse than consensus estimate of $2.83. Revs meanwhile, rose 31.5% on a year-over-year basis to $802 million versus forecast of $781.54 million.
On valuation measures, Regeneron Pharmaceuticals, Inc. shares are currently priced at 137.09x this year’s forecasted earnings compared to the industry’s -17.09x earnings multiple. Ticker has a PEG and forward P/E ratio of 2.17 and 35.00, respectively. Price/Sales for the same period is 15.33 while EPS is $2.93. Currently there are 14 analysts that rate REGN a ‘Buy’, 7 rate it a ‘Hold’. No analyst rates it a ‘Sell’. REGN has a median Wall Street price target of $450.00 with a high target of $519.00.
In the past 52 weeks, shares of Tarrytown, New York-based biopharmaceutical company have traded between a low of $269.50. Shares are up 33.33% year-over-year ; down 2.57% year-to-date.
Allergan Inc. (AGN) was downgraded by Susquehanna analysts to ‘Neutral’ from ‘Positive’ rating Tuesday. Allergan shares were up 1.45% at $226.35 in mid-day trade, moving within a 52-week range of $115.94 to $228.43.
AGN shares have gained 88% over the past 52 weeks, while the S&P 500 index has surged 12.47% in the same period.
Shares of HCP, Inc. (HCP) are down 1.84% in mid-day trading Tuesday, after the company was downgraded to ‘Underperform’ from ‘Neutral’ by analysts at Mizuho this morning. Analysts at the brokerage firm also lowered their 12-month base case estimate on the name to $37 from $49.
HCP, Inc. shares have gained 10.41% over the past 12 months. Ticker dropped 75c to $42.90 in recent trading.
Shares of Transocean Ltd. (RIG) are down 5.58% to $19.33 after Credit Suisse (CS) downgraded its rating on the name to ‘Underperform’ from ‘Neutral’.
Transocean Ltd., currently valued at $6.98B, has a median Wall Street price target of $15.00 with a high target of $33.01. Approximately 11.78M shares have already changed hands, compared to the stock’s average daily volume of 15.17M.
In the past 52 weeks, shares of Vernier, Switzerland-based oil driller have traded between a low of $14.50 and a high of $46.12 with the 50-day MA and 200-day MA located at $17.12 and $27.70 levels, respectively. Additionally, shares of RIG trade at a P/E ratio of -0.10 and have a Relative Strength Index (RSI) and MACD indicator of 61.24 and +2.02, respectively.
The stock is down more than 20% this year and has fallen roughly 58% over the past 12 months.